Literature DB >> 28839560

Prolonged cholestasis induced by endoscopic retrograde cholangiopancreatography.

Olomuza Patani1, Sian L Foulkes1, Ramatoulie Njie1, Richard J Aspinall1.   

Abstract

The case of a 54-year-old woman who presented with choledocholithiasis and underwent successful endoscopic stone extraction to clear the common bile duct is described. However, her jaundice and liver biochemistry continued to deteriorate despite repeat endoscopic retrograde cholangiopancreatography (ERCP), with further imaging confirming a patent biliary tree. The clinical, radiological and pathological features were in keeping with prolonged cholestasis as a complication of ERCP. The pathophysiology of this unusual syndrome and the therapeutic options available are discussed.

Entities:  

Year:  2010        PMID: 28839560      PMCID: PMC5536780          DOI: 10.1136/fg.2009.001099

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  11 in total

Review 1.  Therapeutic biliary endoscopy.

Authors:  M Mutignani; A Tringali; G Costamagna
Journal:  Endoscopy       Date:  2004-02       Impact factor: 10.093

2.  ASGE Technology Status Evaluation Report: radiographic contrast media used in ERCP.

Authors:  Daniel Mishkin; Steven Carpenter; Joseph Croffie; Ram Chuttani; James DiSario; Nadeem Hussain; Julia Liu; Lehel Somogyi; William Tierney; Bret T Petersen
Journal:  Gastrointest Endosc       Date:  2005-10       Impact factor: 9.427

3.  ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas.

Authors:  Douglas G Adler; Todd H Baron; Raquel E Davila; James Egan; William K Hirota; Jonathan A Leighton; Waqar Qureshi; Elizabeth Rajan; Marc J Zuckerman; Robert Fanelli; Jo Wheeler-Harbaugh; Douglas O Faigel
Journal:  Gastrointest Endosc       Date:  2005-07       Impact factor: 9.427

Review 4.  Sepsis-induced cholestasis.

Authors:  Nisha Chand; Arun J Sanyal
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

5.  Persistent cholestatic jaundice after ERCP.

Authors:  Hannah M Lee; Peter A L Bonis; Marshall M Kaplan
Journal:  Am J Gastroenterol       Date:  2006-01       Impact factor: 10.864

Review 6.  Drug-related hepatotoxicity.

Authors:  Victor J Navarro; John R Senior
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

Review 7.  Guidelines on the management of common bile duct stones (CBDS).

Authors:  E J Williams; J Green; I Beckingham; R Parks; D Martin; M Lombard
Journal:  Gut       Date:  2008-03-05       Impact factor: 23.059

8.  Can ERCP contrast agents cause pseudomicrolithiasis? Their effect on the final outcome of bile analysis in patients with suspected microlithiasis.

Authors:  V K Parasher; K Romain; R Sukumar; J Jordan
Journal:  Gastrointest Endosc       Date:  2000-04       Impact factor: 9.427

9.  Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study of 10,000 cases.

Authors:  M K Bilbao; C T Dotter; T G Lee; R M Katon
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

10.  Plasmapheresis and corticosteroid treatment for persistent jaundice after successful drainage of common bile duct stones by endoscopic retrograde cholangiography.

Authors:  Ulku Saritas; Bunyamin Aydin; Yucel Ustundag
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

View more
  2 in total

Review 1.  Prolonged cholestasis following endoscopic retrograde cholangiopancreatography, a rare complication of contrast agent induced liver injury: A case report and literature review.

Authors:  Cheng-Kuan Lin; Wen-Chih Huang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

2.  Diagnostic value of endoscopic retrograde cholangiopancreatography and therapeutic value of endoscopic sphincterotomy in dogs with suspected hepatobiliary disorders.

Authors:  Vahideh Rahmani; Thomas Spillmann; Jorma Halttunen; Pernilla Syrjä; Mirja Ruohoniemi
Journal:  BMC Vet Res       Date:  2022-04-21       Impact factor: 2.792

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.